News | December 12, 2007

Enrollment Completed for DIVERGE Trial of Drug-Eluting Stent System for Bifurcation Lesions

December 13, 2007 - Devax Inc. announced that it has completed patient enrollment in the DIVERGE clinical trial evaluating its novel AXXESS Bifurcation Stent System.

The prospective, multi-center trial that enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions. Bifurcation lesions are areas of atherosclerotic disease occurring at a location where one large vessel divides into two smaller vessels.

"The DIVERGE trial and the AXXESS System are important because of the frequent presentation of bifurcation lesions in our daily clinical practice," said Stefan Verheye, M.D., Ph.D., co-principal investigator of the study and co-director of the Antwerp Cardiovascular Institute at the Middelheim Hospital in Antwerp, Belgium. "Conventional drug-eluting stents are technically challenging to place in bifurcation lesions since they are not designed for the unique anatomical characteristics of coronary bifurcations. As a result, these types of lesions are associated with high complication and restenosis rates compared to conventional lesions. We will submit the data for the next appropriate medical meeting."

The Devax AXXESS Biolimus A9 Eluting Bifurcation Stent System is a proprietary self-expanding Nitinol stent specifically engineered for the treatment of coronary and vascular bifurcation lesions. The stent is coated with Biolimus A9(R), a drug uniquely formulated to prevent restenosis in a coronary artery and a next-generation bioabsorbable polymer, Polylactic acid (PLA), which is designed to release the drug over time. The conical shape of the stent is specifically designed to conform to the anatomy of the bifurcation and to provide interventional cardiologists with the ability to treat the bifurcation without compromising access to the side branch.

To date, more than 500 patients worldwide have been treated using the AXXESS Bifurcation Stent System. More than 400 patients have received the drug-eluting version of the stent.

For more information: www. devax.net

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init